At 0 2 0 2 O
least 3 8 3 8 O
one 9 12 9 12 B-lower_bound
extracranial 13 25 13 25 O
measurable 26 36 26 36 O
lesion 37 43 37 43 O
as 44 46 44 46 O
defined 47 54 47 54 O
by 55 57 55 57 O
RECIST 58 64 58 64 O
1.1 65 68 65 68 O

Be 0 2 69 71 O
neurologically 3 17 72 86 O
stable 18 24 87 93 O
within 25 31 94 100 O
at 32 34 101 103 O
least 35 40 104 109 O
1 41 42 110 111 B-lower_bound
week 43 47 112 116 I-lower_bound
prior 48 53 117 122 I-lower_bound
to 54 56 123 125 O
the 57 60 126 129 O
first 61 66 130 135 O
dose 67 71 136 140 O
of 72 74 141 143 O
study 75 80 144 149 B-treatment
drug 81 85 150 154 I-treatment

Dose 0 4 155 159 O
of 5 7 160 162 O
steroids 8 16 163 171 B-treatment
must 17 21 172 176 O
be 22 24 177 179 O
stable 25 31 180 186 O
for 32 35 187 190 O
5 36 37 191 192 B-upper_bound
days 38 42 193 197 I-upper_bound
before 43 49 198 204 O
the 50 53 205 208 O
baseline 54 62 209 217 O
brain 63 68 218 223 O
MRI 69 72 224 227 B-treatment

Histologically 0 14 228 242 O
or 15 17 243 245 O
cytologically 18 31 246 259 O
confirmed 32 41 260 269 O
diagnosis 42 51 270 279 O
of 52 54 280 282 O
metastatic 55 65 283 293 O
NSCLC 66 71 294 299 B-cancer
according 72 81 300 309 O
to 82 84 310 312 O
the 85 88 313 316 O
7th 89 92 317 320 O
edition 93 100 321 328 O
of 101 103 329 331 O
the 104 107 332 335 O
AJCC 108 112 336 340 O
Cancer 113 119 341 347 O
Staging 120 127 348 355 O
Manual 128 134 356 362 O

In 0 2 363 365 O
addition 3 11 366 374 O
, 11 12 374 375 O
the 13 16 376 379 O
NSCLC 17 22 380 385 B-cancer
must 23 27 386 390 O
harbor 28 34 391 397 O
an 35 37 398 400 O
ALK 38 41 401 404 O
rearrangement 42 55 405 418 O
, 55 56 418 419 O
as 57 59 420 422 O
assessed 60 68 423 431 O
using 69 74 432 437 O
the 75 78 438 441 O
FDA 79 82 442 445 O
approved 83 91 446 454 O
Vysis 92 97 455 460 O
ALK 98 101 461 464 O
Break 102 107 465 470 O
Apart 108 113 471 476 O
FISH 114 118 477 481 O
Probe 119 124 482 487 O
Kit 125 128 488 491 O
( 129 130 492 493 O
Abbott 130 136 493 499 O
Molecular 137 146 500 509 O
Inc. 147 151 510 514 O
) 151 152 514 515 O
test 153 157 516 520 O
and 158 161 521 524 O
scoring 162 169 525 532 O
algorithm 170 179 533 542 O
( 180 181 543 544 O
including 181 190 544 553 O
positivity 191 201 554 564 O
criteria 202 210 565 573 O
) 210 211 573 574 O

Patient 0 7 575 582 O
has 8 11 583 586 O
a 12 13 587 588 O
WHO 14 17 589 592 B-clinical_variable
performance 18 29 593 604 I-clinical_variable
status 30 36 605 611 I-clinical_variable
0 37 38 612 613 B-lower_bound
- 38 39 613 614 O
2 39 40 614 615 B-upper_bound

Patient 0 7 616 623 O
has 8 11 624 627 O
impairment 12 22 628 638 B-chronic_disease
of 23 25 639 641 I-chronic_disease
GI 26 28 642 644 I-chronic_disease
function 29 37 645 653 I-chronic_disease
or 38 40 654 656 O
GI 41 43 657 659 B-chronic_disease
disease 44 51 660 667 I-chronic_disease
that 52 56 668 672 O
may 57 60 673 676 O
significantly 61 74 677 690 O
alter 75 80 691 696 O
the 81 84 697 700 O
absorption 85 95 701 711 O
of 96 98 712 714 O
ceritinib 99 108 715 724 B-treatment
( 109 110 725 726 O
e.g. 110 114 726 730 O
, 114 115 730 731 O
ulcerative 116 126 732 742 B-chronic_disease
diseases 127 135 743 751 I-chronic_disease
, 135 136 751 752 O
uncontrolled 137 149 753 765 O
nausea 150 156 766 772 O
, 156 157 772 773 O
vomiting 158 166 774 782 O
, 166 167 782 783 O
diarrhea 168 176 784 792 O
, 176 177 792 793 O
or 178 180 794 796 O
malabsorption 181 194 797 810 B-chronic_disease
syndrome 195 203 811 819 I-chronic_disease
) 203 204 819 820 O

Patient 0 7 821 828 O
has 8 11 829 832 O
life 12 16 833 837 B-clinical_variable
expectancy 17 27 838 848 I-clinical_variable
≥ 28 29 849 850 O
6 30 31 851 852 B-lower_bound
weeks 32 37 853 858 I-lower_bound

Patient 0 7 859 866 O
has 8 11 867 870 O
other 12 17 871 876 O
severe 18 24 877 883 O
, 24 25 883 884 O
acute 26 31 885 890 O
, 31 32 890 891 O
or 33 35 892 894 O
chronic 36 43 895 902 O
medical 44 51 903 910 B-chronic_disease
conditions 52 62 911 921 I-chronic_disease
including 63 72 922 931 O
uncontrolled 73 85 932 944 B-chronic_disease
diabetes 86 94 945 953 I-chronic_disease
mellitus 95 103 954 962 I-chronic_disease
or 104 106 963 965 O
psychiatric 107 118 966 977 B-chronic_disease
conditions 119 129 978 988 I-chronic_disease
or 130 132 989 991 O
laboratory 133 143 992 1002 O
abnormalities 144 157 1003 1016 O
that 158 162 1017 1021 O
in 163 165 1022 1024 O
the 166 169 1025 1028 O
opinion 170 177 1029 1036 O
of 178 180 1037 1039 O
the 181 184 1040 1043 O
investigator 185 197 1044 1056 O
may 198 201 1057 1060 O
increase 202 210 1061 1069 O
the 211 214 1070 1073 O
risk 215 219 1074 1078 O
associated 220 230 1079 1089 O
with 231 235 1090 1094 O
study 236 241 1095 1100 O
participation 242 255 1101 1114 O
, 255 256 1114 1115 O
or 257 259 1116 1118 O
that 260 264 1119 1123 O
may 265 268 1124 1127 O
interfere 269 278 1128 1137 O
with 279 283 1138 1142 O
the 284 287 1143 1146 O
interpretation 288 302 1147 1161 O
of 303 305 1162 1164 O
study 306 311 1165 1170 O
results 312 319 1171 1178 O

Patient 0 7 1179 1186 O
is 8 10 1187 1189 O
receiving 11 20 1190 1199 O
unstable 21 29 1200 1208 O
or 30 32 1209 1211 O
increasing 33 43 1212 1222 O
doses 44 49 1223 1228 O
of 50 52 1229 1231 O
corticosteroids 53 68 1232 1247 B-treatment

Patient 0 7 1248 1255 O
with 8 12 1256 1260 O
a 13 14 1261 1262 O
concurrent 15 25 1263 1273 O
malignancy 26 36 1274 1284 B-cancer
or 37 39 1285 1287 O
history 40 47 1288 1295 O
of 48 50 1296 1298 O
a 51 52 1299 1300 O
malignant 53 62 1301 1310 B-cancer
disease 63 70 1311 1318 I-cancer
other 71 76 1319 1324 O
than 77 81 1325 1329 O
NSCLC 82 87 1330 1335 B-cancer
that 88 92 1336 1340 O
has 93 96 1341 1344 O
been 97 101 1345 1349 O
diagnosed 102 111 1350 1359 O
and/or 112 118 1360 1366 O
required 119 127 1367 1375 O
therapy 128 135 1376 1383 B-treatment
within 136 142 1384 1390 O
the 143 146 1391 1394 O
past 147 151 1395 1399 B-upper_bound
3 152 153 1400 1401 I-upper_bound
years 154 159 1402 1407 I-upper_bound

Patients 0 8 1408 1416 O
may 9 12 1417 1420 O
have 13 17 1421 1425 O
received 18 26 1426 1434 O
prior 27 32 1435 1440 B-treatment
chemotherapy 33 45 1441 1453 I-treatment
, 45 46 1453 1454 O
crizotinib 47 57 1455 1465 B-treatment
( 58 59 1466 1467 O
other 59 64 1467 1472 O
ALK 65 68 1473 1476 B-treatment
inhibitors 69 79 1477 1487 I-treatment
are 80 83 1488 1491 O
not 84 87 1492 1495 O
allowed 88 95 1496 1503 O
) 95 96 1503 1504 O
, 96 97 1504 1505 O
biologic 98 106 1506 1514 B-treatment
therapy 107 114 1515 1522 I-treatment
or 115 117 1523 1525 O
other 118 123 1526 1531 O
investigational 124 139 1532 1547 B-treatment
agents 140 146 1548 1554 I-treatment

Patients 0 8 1555 1563 O
may 9 12 1564 1567 O
or 13 15 1568 1570 O
may 16 19 1571 1574 O
not 20 23 1575 1578 O
have 24 28 1579 1583 O
neurological 29 41 1584 1596 O
symptoms 42 50 1597 1605 O
but 51 54 1606 1609 O
must 55 59 1610 1614 O
be 60 62 1615 1617 O
able 63 67 1618 1622 O
to 68 70 1623 1625 O
swallow 71 78 1626 1633 O
and 79 82 1634 1637 O
retain 83 89 1638 1644 O
oral 90 94 1645 1649 B-treatment
medication 95 105 1650 1660 I-treatment

Patients 0 8 1661 1669 O
must 9 13 1670 1674 O
be 14 16 1675 1677 O
diagnosed 17 26 1678 1687 O
with 27 31 1688 1692 O
leptomeningeal 32 46 1693 1707 B-cancer
carcinomatosis 47 61 1708 1722 I-cancer

Patients 0 8 1723 1731 O
must 9 13 1732 1736 O
have 14 18 1737 1741 O
active 19 25 1742 1748 O
brain 26 31 1749 1754 B-cancer
metastases 32 42 1755 1765 I-cancer
from 43 47 1766 1770 O
NSCLC 48 53 1771 1776 B-cancer
, 53 54 1776 1777 O
confirmed 55 64 1778 1787 O
by 65 67 1788 1790 O
Gadolinium 68 78 1791 1801 B-treatment
- 78 79 1801 1802 I-treatment
enhanced 79 87 1802 1810 I-treatment
MRI 88 91 1811 1814 I-treatment
without 92 99 1815 1822 O
concomitant 100 111 1823 1834 O
leptomeningeal 112 126 1835 1849 B-cancer
carcinomatosis 127 141 1850 1864 I-cancer

Patients 0 8 1865 1873 O
must 9 13 1874 1878 O
have 14 18 1879 1883 O
recovered 19 28 1884 1893 O
from 29 33 1894 1898 O
all 34 37 1899 1902 O
toxicities 38 48 1903 1913 O
related 49 56 1914 1921 O
to 57 59 1922 1924 O
prior 60 65 1925 1930 B-treatment
anticancer 66 76 1931 1941 I-treatment
therapies 77 86 1942 1951 I-treatment
to 87 89 1952 1954 O
grade 90 95 1955 1960 O
≤ 96 97 1961 1962 O
1 98 99 1963 1964 B-upper_bound
( 100 101 1965 1966 O
CTCAE 101 106 1966 1971 O
v 107 108 1972 1973 O
4.03 109 113 1974 1978 O
) 113 114 1978 1979 O

Patients 0 8 1980 1988 O
must 9 13 1989 1993 O
wait 14 18 1994 1998 O
for 19 22 1999 2002 O
the 23 26 2003 2006 O
central 27 34 2007 2014 O
laboratory 35 45 2015 2025 O
result 46 52 2026 2032 O
of 53 55 2033 2035 O
the 56 59 2036 2039 O
ALK 60 63 2040 2043 O
rearrangement 64 77 2044 2057 O
status 78 84 2058 2064 O
before 85 91 2065 2071 O
initiating 92 102 2072 2082 O
treatment 103 112 2083 2092 B-treatment
with 113 117 2093 2097 I-treatment
ceritinib 118 127 2098 2107 I-treatment

Patients 0 8 2108 2116 O
who 9 12 2117 2120 O
need 13 17 2121 2125 O
whole 18 23 2126 2131 B-treatment
brain 24 29 2132 2137 I-treatment
radiation 30 39 2138 2147 I-treatment
to 40 42 2148 2150 O
control 43 50 2151 2158 O
the 51 54 2159 2162 O
brain 55 60 2163 2168 B-cancer
metastases 61 71 2169 2179 I-cancer

Patients 0 8 2180 2188 O
with 9 13 2189 2193 O
any 14 17 2194 2197 O
grade 18 23 2198 2203 O
of 24 26 2204 2206 O
alopecia 27 35 2207 2215 B-chronic_disease
are 36 39 2216 2219 O
allowed 40 47 2220 2227 O
to 48 50 2228 2230 O
enter 51 56 2231 2236 O
the 57 60 2237 2240 O
study 61 66 2241 2246 O

Planning 0 8 2247 2255 O
of 9 11 2256 2258 O
any 12 15 2259 2262 O
brain 16 21 2263 2268 B-treatment
local 22 27 2269 2274 I-treatment
treatment 28 37 2275 2284 I-treatment
( 38 39 2285 2286 O
including 39 48 2286 2295 O
but 49 52 2296 2299 O
not 53 56 2300 2303 O
limited 57 64 2304 2311 O
to 65 67 2312 2314 O
surgery 68 75 2315 2322 B-treatment
, 75 76 2322 2323 O
stereotactic 77 89 2324 2336 B-treatment
radiosurgery 90 102 2337 2349 I-treatment
, 102 103 2349 2350 O
whole 104 109 2351 2356 B-treatment
brain 110 115 2357 2362 I-treatment
radiation 116 125 2363 2372 I-treatment
, 125 126 2372 2373 O
intrathecal 127 138 2374 2385 B-treatment
chemotherapy 139 151 2386 2398 I-treatment
) 151 152 2398 2399 O
following 153 162 2400 2409 O
the 163 166 2410 2413 O
administration 167 181 2414 2428 O
of 182 184 2429 2431 O
the 185 188 2432 2435 O
first 189 194 2436 2441 O
dose 195 199 2442 2446 O
of 200 202 2447 2449 O
study 203 208 2450 2455 B-treatment
drug 209 213 2456 2460 I-treatment

completely 0 10 2461 2471 O
resected 11 19 2472 2480 O
basal 20 25 2481 2486 B-cancer
cell 26 30 2487 2491 I-cancer
and 31 34 2492 2495 O
squamous 35 43 2496 2504 B-cancer
cell 44 48 2505 2509 I-cancer
skin 49 53 2510 2514 I-cancer
cancers 54 61 2515 2522 I-cancer
, 61 62 2522 2523 O
and 63 66 2524 2527 O
completely 67 77 2528 2538 O
resected 78 86 2539 2547 O
carcinoma 87 96 2548 2557 B-cancer
in 97 99 2558 2560 I-cancer
situ 100 104 2561 2565 I-cancer
of 105 107 2566 2568 O
any 108 111 2569 2572 O
type 112 116 2573 2577 O

